Stopping immune suppressants in older adults with UC
Part of Digestive system clinical trials.
This trial tests if older adults with ulcerative colitis who have been in remission for a long time can safely stop taking their immune-suppressing medication (thiopurine). It may help reduce medication side effects while keeping the disease under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older.
- You have had ulcerative colitis for a while and have been in remission (no active symptoms) for at least 1 year, based on both symptoms and a colonoscopy.
- You have been taking a thiopurine drug (azathioprine or mercaptopurine) for at least 5 years, at a stable dose without side effects in the last year.
- You have been in clinical remission for at least 3 years without needing steroids or biologic drugs (topical treatments and stable mesalazine are allowed).
- You have had a colonoscopy in the last 6 months showing no inflammation, and two stool tests 1 month apart showing low calprotectin levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
This trial tests if patients with ulcerative colitis or Crohn's disease who are already stable on stronger medications (biologics or immunomodulators) can safely stop taking their 5-ASA (mesalamine) pill. It aims to see if stopping 5-ASA affects disease control.
This study tests whether it is safe to stop taking acid-reducing pills (PPIs) for people with inactive IBD. If you have been on a PPI for over 6 months and your IBD is stable, you may be able to join.
This trial tests whether taking selenium supplements can help people with moderate to severe ulcerative colitis that is being treated with advanced therapies (biologics). The goal is to see if selenium can improve symptoms and reduce inflammation.
This trial tests whether people with ulcerative colitis who are in deep remission (no symptoms and healed gut lining) can safely stop taking their JAK inhibitor (tofacitinib, upadacitinib, or filgotinib) instead of continuing the usual maintenance dose. It aims to see if stopping is as effective and safer over time.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.